Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120
Crossref DOI link: https://doi.org/10.1007/s10157-017-1447-0
Published Online: 2017-07-24
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schulman, Gerald
Berl, Tomas
Beck, Gerald J.
Remuzzi, Giuseppe
Ritz, Eberhard
Shimizu, Miho
Kikuchi, Mami
Shobu, Yuko
License valid from 2017-07-24